Replies to post #241123 on Biotech Values

[DewDiligence]

PRDS—Ritonavir-related excerpt from S-1 filing (for registration of insider shares):

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001822711/000119312522014843/d299901ds1.htm

In August 2021, we initiated our first-in-human trial for PBI-0451. This trial is anticipated to enroll up to 180 healthy volunteers. The Phase 1 study is a placebo-controlled, blinded, randomized, dose escalation study of PBI-0451 in healthy volunteers designed to evaluate the safety, tolerability, and pharmacokinetics of PBI-0451 after single and multiple ascending doses.

This study will also evaluate the drug-drug interaction potential of PBI-0451, including upon its coadministration with ritonavir.

Emphasis added.

[DewDiligence]

PRDS is leaning toward a 1400mg daily dose of PBI-0451 (two 350mg tablets BID, taken with food), according to the company’s presentation at CROI this week:

https://ir.pardesbio.com/static-files/a8fa45a7-4cea-4827-a623-154c807c7372 (slide #19)

1400mg/day is a lot of drug, even for a short-course regimen.